

Handbook of

ANALYTICAL VALIDATION

Michael E. Swartz
Ira S. Krull



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

Contents

Preface.....	xiii
Chapter 1 Introduction to Analytical Method Validation.....	1
1.1 Introduction	1
1.2 Drug Development Process	1
1.3 FDA Hierarchy and Organization	3
1.4 International Conference on Harmonization.....	4
1.4.1 Structure of the ICH.....	5
1.4.1.1 European Commission of the European Union (EU)	6
1.4.1.2 European Federation of Pharmaceutical Industries and Associations (EFPIA)	6
1.4.1.3 Ministry of Health and Welfare, Japan (MHW)	6
1.4.1.4 Japan Pharmaceutical Manufacturers Association (JPMA).....	6
1.4.1.5 US Food and Drug Administration (FDA) ...	6
1.4.1.6 Pharmaceutical Research and Manufacturers of America (PhRMA)	6
1.4.1.7 Observers	7
1.4.2 ICH Administration.....	7
1.4.3 ICH Harmonization Process	7
1.4.3.1 Step 1	7
1.4.3.2 Step 2	8
1.4.3.3 Step 3	8
1.4.3.4 Step 4	8
1.4.3.5 Step 5	8
1.4.4 ICH Harmonization Initiatives.....	8
1.5 AMV Guidance	9
1.5.1 Types of Analytical Procedures	11
1.5.2 Reference Standards.....	11
1.5.3 Certificate of Analysis.....	11
1.5.4 Characterization of a Reference Standard.....	12
1.5.5 Content and Format for Analytical Methods and Procedures.....	13
1.5.6 Content and Processing of the Method Validation Package.....	13
1.5.6.1 Selection and Shipment of Samples.....	13
1.5.6.2 Responsibilities	14
1.6 Validation Process	15

1.6.1	Software Validation.....	17
1.6.2	Analytical Instrument Qualification	17
1.6.3	System Suitability.....	18
1.7	Training	18
1.8	Conclusion	20
	References	20
Chapter 2	Analytical Instrument Qualification	23
2.1	Introduction	23
2.2	Components of Data Quality.....	23
2.3	AIQ Process.....	24
2.3.1	Design Qualification.....	24
2.3.2	Installation Qualification (IQ).....	25
2.3.3	Operational Qualification (OQ)	26
2.3.3.1	HPLC Pump Flow Rate Accuracy.....	27
2.3.3.2	Gradient Accuracy.....	28
2.3.3.3	Injector Accuracy.....	28
2.3.3.4	Column Oven and Auto Sampler Temperature	29
2.3.3.5	UV Detector Wavelength Accuracy and Linearity.....	30
2.3.4	Performance Qualification (PQ)	30
2.3.5	Preventative Maintenance and Repairs	32
2.4	Roles and Responsibilities.....	34
2.5	Software Validation and Change Control.....	34
2.6	AIQ Documentation	34
2.7	Instrument Categories	35
2.8	Conclusion	36
	References	36
Chapter 3	HPLC Method Development and Optimization with Validation in Mind.....	37
3.1	Introduction	37
3.2	HPLC Method Development Approaches	37
3.3	Method Goals	38
3.4	HPLC Method Development Instrumentation	39
3.4.1	HPLC Systems for Column and Method Scouting	44
3.4.2	Automated HPLC Method Development Systems	47
3.4.3	UHPLC in Method Development Systems.....	49
3.4.4	Solvent Management	50
3.4.5	Sample Management	51
3.4.6	Detection	51
3.4.7	Column Module.....	55
3.4.8	Columns for Method Development	56

3.4.9	Mobile Phase Considerations	57
3.5	Method Optimization	58
3.6	Summary	59
	References	59
Chapter 4	Method Validation Basics	61
4.1	Introduction	61
4.2	Method Validation Guidelines.....	61
4.3	Terms and Definitions	62
4.3.1	Accuracy.....	63
4.3.2	Precision.....	65
4.3.2.1	Repeatability.....	65
4.3.2.2	Intermediate Precision.....	65
4.3.2.3	Reproducibility	66
4.3.2.4	Ruggedness	67
4.3.3	Specificity.....	68
4.3.4	Detection Limit	70
4.3.5	Quantitation Limit.....	71
4.3.6	Linearity and Range.....	73
4.3.7	Robustness.....	74
4.4	Validation according to Method Type.....	75
4.5	Documentation	75
4.5.1	Validation Protocol.....	75
4.5.2	Test Method.....	76
4.5.3	Validation Report	77
4.6	Summary	78
	References	78
Chapter 5	Robustness and System Suitability.....	81
5.1	Introduction	81
5.2	Robustness Studies for Method Validation	81
5.3	Robustness Study Experimental Design.....	83
5.3.1	Screening Designs.....	83
5.3.1.1	Full Factorial Designs.....	84
5.3.1.2	Fractional Factorial Designs.....	84
5.3.1.3	Plackett–Burman Designs	86
5.3.2	Determining the Factors, Measuring the Results.....	86
5.4	Analyzing the Results.....	89
5.5	Documentation and Reporting	90
5.6	System Suitability Tests.....	91
5.7	System Suitability Standards.....	92
5.8	System Suitability Protocol	93
5.9	Method Adjustments to Meet System Suitability Requirements.....	94

5.9.1	pH Adjustments	96
5.9.2	Column Length, Diameter, and Particle Size Adjustments: Scaling the Separation.....	96
5.10	Conclusion	98
	References	99

Chapter 6 Setting Specifications and Investigating Out-of-Specification

	Results	101
6.1	Introduction	101
6.2	Guidance for Setting Specifications	101
6.3	General Concepts for Developing and Setting Specifications.....	102
6.3.1	Limited Data Available at Filing.....	102
6.3.2	Periodic or Skip Testing	103
6.3.3	Release versus Shelf-Life Acceptance Criteria	103
6.3.4	In-Process Tests.....	103
6.3.5	Parametric Release.....	103
6.3.6	Pharmacopeial Tests.....	103
6.4	Universal Tests/Criteria	104
6.5	Specific Tests/Criteria: New Drug Substances	104
6.5.1	Physicochemical Properties	104
6.5.2	Particle Size.....	104
6.5.3	Polymorphic Forms.....	104
6.5.4	Chiral-Drug Substance.....	105
6.5.5	Chiral-Drug Product	105
6.5.6	Water Content.....	105
6.5.7	Inorganic Impurities.....	105
6.5.8	Microbial Limits	106
6.6	Specific Tests/Criteria: New Solid Oral Drug Products.....	106
6.6.1	Dissolution.....	106
6.6.2	Disintegration.....	106
6.6.3	Hardness/Friability.....	106
6.6.4	Uniformity of Dosage Units	107
6.7	Specific Tests/Criteria: New Oral Liquid Drug Products.....	107
6.8	Specific Tests/Criteria: Parenteral Drug Products.....	107
6.9	Decision Trees	108
6.10	OOS Background.....	108
6.11	Preventing OOS Results	111
6.12	Identifying and Assessing OOS Test Results	111
6.13	Investigating OOS Test Results	113
6.13.1	General Investigative Principles.....	113
6.13.2	Laboratory Phase of an Investigation.....	113
6.13.2.1	Assignable Cause.....	114
6.13.2.2	No Assignable Cause/Retest.....	115

6.13.2.3	No Assignable Cause/Result Is Confirmed.....	115
6.13.3	Retesting.....	115
6.13.4	Resampling.....	115
6.13.5	Averaging (Resampling Testing Data).....	116
6.13.6	Outlier Tests.....	116
6.14	Concluding the OOS Investigation.....	116
6.15	Conclusion.....	117
	References.....	117
Chapter 7	Validation by Type of Method.....	119
7.1	Introduction.....	119
7.1.1	Category I Methods.....	119
7.1.2	Category II Methods.....	120
7.1.3	Category III Methods.....	121
7.1.4	Category IV Methods.....	121
7.2	Validation of Impurity Methods.....	121
7.2.1	Classification of Impurities.....	122
7.2.2	Impurity Method Validation Documentation.....	124
7.2.2.1	Reporting Impurity Content of API Batches.....	124
7.2.3	Specificity in Impurity Methods.....	125
7.2.4	Accuracy in Impurity Methods.....	126
7.3	Stability Indicating Method.....	126
7.3.1	Developing and Validating SIMS.....	127
7.3.1.1	Generating the Sample.....	127
7.3.1.2	Developing the LC Method.....	128
7.3.1.3	Manipulating Chromatographic Selectivity during Method Development..	129
7.3.1.4	Evaluating Specificity during SIM Development.....	131
7.3.1.5	New Technology for SIM Development ...	134
7.3.2	SIM Validation.....	135
7.4	Developing and Validating Dissolution Procedures.....	135
7.4.1	Qualification and Calibration.....	136
7.4.2	Dissolution Procedure Development.....	137
7.4.2.1	Dissolution Medium.....	137
7.4.2.2	Dissolution Apparatus.....	138
7.4.2.3	Dissolution Study Design.....	139
7.4.2.4	Assaying the Results.....	140
7.4.3	Dissolution Procedure Validation.....	141
7.4.3.1	Specificity/Placebo Interference.....	141
7.4.3.2	Linearity and Range.....	142
7.4.3.3	Accuracy and Recovery.....	142

	7.4.3.4	Precision	142
	7.4.3.5	Robustness	143
	7.4.3.6	Remaining Validation Tests.....	143
7.5		Bioanalytical Methods.....	143
	7.5.1	Reference Standard Preparation.....	145
	7.5.2	Bioanalytical Method Development and Validation ...	145
		7.5.2.1 Selectivity	145
		7.5.2.2 Accuracy, Precision, and Recovery	146
		7.5.2.3 Calibration/Standard Curve.....	146
		7.5.2.4 Bioanalytical Sample Stability	147
	7.5.3	Routine Application of the Bioanalytical Method ...	148
	7.5.4	Bioanalytical Method Documentation	150
7.6		Validating Peptide Mapping Methods.....	150
	7.6.1	Biocharacterization of Peptides.....	151
		7.6.1.1 Selective Cleavage of the Protein Peptide Bonds	151
		7.6.1.2 Chromatographic Separation.....	153
	7.6.2	Validation of Peptide Mapping Methods.....	154
		7.6.2.1 Robustness	154
		7.6.2.2 Limit of Detection (LOD).....	154
		7.6.2.3 Precision	155
		7.6.2.4 System Suitability	155
	7.6.3	Mass Spectrometry in Peptide Mapping	156
7.7		Cleaning Method Validation	157
	7.7.1	General Requirements.....	157
	7.7.2	Equipment Cleaning.....	158
		7.7.2.1 Sampling Methods.....	159
	7.7.3	Validating Cleaning Methods	159
	7.7.4	Setting Residue Limits	160
7.8		Conclusion	161
		References	162

Chapter 8		Analytical Method Transfer	165
	8.1	Introduction	165
	8.2	Terms, Definitions, and Responsibilities	165
	8.3	Analytical Method Transfer Options.....	166
		8.3.1 Comparative Testing.....	167
		8.3.2 Co-Validation between Laboratories.....	167
		8.3.3 Method Validation and Revalidation.....	167
		8.3.4 Transfer Waiver	167
	8.4	Elements of AMT	168
		8.4.1 Preapproved Test Plan Protocol	168
		8.4.2 Description of Method/Test Procedures	168
		8.4.3 Description and Rationale of Test Requirements.....	168
		8.4.4 Acceptance Criteria.....	169

8.5 Documentation of Results: AMT Report 169

8.6 Potential AMT Pitfalls 169

 8.6.1 Instrument Considerations 171

 8.6.2 Column Considerations 172

 8.6.3 General Considerations 172

8.7 Conclusion 172

References 173

Chapter 9 Implementing New Technology in a Regulated Environment 175

9.1 Introduction 175

9.2 Changes to an Approved Method 175

9.3 What Constitutes a Change to a Method? 176

9.4 Implement an Existing Standard Method..... 177

 9.4.1 Verification 177

 9.4.1.1 Laboratory Personnel..... 178

 9.4.1.2 Approved Procedure 178

 9.4.1.3 Verification Documentation..... 178

 9.4.1.4 Verification Process Examples 179

9.5 Implement an Existing Standard Method with
Adjustments 180

9.6 Implement an Existing Standard Method with Changes..... 181

9.7 Conclusion 182

References 182

Glossary of Terms Related to Chromatographic Method Validation..... 183

Appendix: Example Method Validation Protocol..... 191

Index..... 199